【VivopureX活體用抗體】Anti-IL-10R Mouse IgG2a, Fc Silent™, Kappa 貨號Ab01490-2.3
VivopureX™抗體用於體內研究
VivopureX™抗體是重組小鼠抗體，非常適合在小鼠模型中進行體內研究。該集合包括流行的抗體克隆(antibody clones)，其中許多最初是從大鼠或倉鼠獲得的，Absolute Antibody已將這些抗體克隆工程化為小鼠抗小鼠重組體，以改善研究結果。
與原始抗體形式相比，VivopureX™重組小鼠抗體具有許多優勢，包括：
- 免疫原性降低(Reduced immunogenicity)：在宿主生物體中未誘導出任何中和抗體(neutralizing antibodies)，這意味著該抗體的作用時間更長，並且群體反應更加一致。
- Tailored effector function：增加的Fc受體結合增加了耗盡的潛力，而減少的Fc受體結合減少了阻斷的副作用。
- 增強的效力：在小鼠模型中實現相同反應所需的抗體更少。
- 批次間的可重複性：重組生產可確保最高的可重複性，並確保高純度和低內毒素（<0.5 EU / mg）。
Anti-IL-10R [1B1.3a], Mouse IgG2a, Fc Silent™, Kappa | 貨號Ab01490-2.3
該抗體識別小鼠IL-10R，它是一種細胞表面糖蛋白，是抗炎性IL-10的後代。該抗體識別的表位已定位於小鼠IL-10R細胞外區域內的配體結合結構域。
UniProt Accession Number of Target Protein: Q61727
Alternative Name(s) of Target: CD210; Interleukin-10 receptor subunit; Interleukin-10 receptor subunit alpha; Il10ra Il10r; IL-10 receptor subunit alpha; IL-10R subunit alpha; IL-10RA; CDw210a; Interleukin-10 receptor subunit 1; IL-10R subunit 1; IL-10R1; IBI-3A; 1B1-3A
Immunogen: This antibody was raised by immunising rats with the purified recombinant extracellular region of mouse Interleukin 10 Receptor.
Specificity: This antibody recognises mouse IL-10R which is a cell surface glycoprotein and a receprot for anti-inflammatory IL-10. The epitope recognised by this antibody has been localised to the ligand binding domain within the extracellular region of mouse IL-10R.
Application Notes: 1B1.3a has been widely applied in flow cytometric analyses where the detection of IL-10R was needed. Furthermore, this antibody was also successfully utilised as a blocking agent; one group used it to demonstrate that IL-10 mediates suppressive activity, by targeting its receptor IL-10R with this antibody (Wang et al., 2004). Castro et al. (2000) demonstrated that 1B1.3a is able to make a soluble peptide or protein antigen immunogenic for subsequent Th1 recall responses in a situation when there is an additional signal, such as LPS, activating the immune system. Consequently, this antibody is a hugely promising agent in the potential development of vaccines for immunotherapy. Similarly, Vicari and colleagues (2002) showed that this antibody has an enormous potential as a therapeutic anti-tumour agent when combined with the administration of CpG to stimulate the immune system.
Antibody first published in: O’Farrell et al. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998 Feb 16;17(4):1006-18. PMID:9463379
Note on publication: This article describes the method of generation of antibodies like 1B1.3a.
| Antibody Name [Clone] | Engineered Format | Top Application | Available Bulk Sizes |
| Anti-OX40/CD134 [OX86] | Mouse IgG2a | Agonism | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-PD-1 [RMP1-14] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-CTLA-4 [9D9] | Mouse IgG2a | Blocking, Treg depletion | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-CTLA-4 [9D9] | Mouse IgG2a Fc Silent™ | Blocking, peripheral Treg expansion | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-GITR [DTA-1] | Mouse IgG2a | Agonism | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-CD25 [PC-61.5.3] | Mouse IgG2a | Depletion | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-TIGIT [1B4] | Mouse IgG1 | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-Lag3 [C9B7W] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-CD96 [6A6] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-IL-10R [1B1.3a] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-B7-H4 [7A1-6] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-BTLA [HMBT-6B2] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-Tim-4 [3A1] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-Tim-4 [5G3] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-TIM-2 [RMT2-14] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-Tim-1 [3B3] | Mouse IgG1 | Agonism | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-Tim-3 [2C12] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-CD115/M-CSFR [AFS98] | Mouse IgG2a | Depletion | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-PD-L1 [10F.9G2] | Mouse IgG2b Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-IFN-gamma receptor 1 [GR20] | Mouse IgG2b Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-VISTA [13F3] | Mouse IgG2b Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |
| Anti-CD20 [18B12] | Mouse IgG2a | Depletion | 10 mg, 25 mg, 100 mg |
| Anti-CD4 epitope A [YTS 177.9] | Mouse IgG2a | Depletion | 10 mg, 25 mg, 100 mg |
| Anti-CD4 epitope A [YTS 191.1] | Mouse IgG2a | Depletion | 10 mg, 25 mg, 100 mg |
| Anti-CD8 alpha/Lyt-2 [YTS 169.4] | Mouse IgG2a | Depletion | 10 mg, 25 mg, 100 mg |
| Anti-Ly6G [1A8] | Mouse IgG2a | Depletion | 10 mg, 25 mg, 100 mg |
| Anti-CD200R [OX131] | Mouse IgG1 Fc Silent™ | Blocking | 10 mg, 25 mg, 100 mg |
| Anti-PD-L2 [TY25] | Mouse IgG2a Fc Silent™ | Blocking | 1 mg, 10 mg, 25 mg, 100 mg |